📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. (2017)

First Author: Boeree MJ

Attributed to: Tuberculosis Treatment Trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1473-3099(16)30274-2

PubMed Identifier: 28100438

Publication URI: http://europepmc.org/abstract/MED/28100438

Type: Journal Article/Review

Volume: 17

Parent Publication: The Lancet. Infectious diseases

Issue: 1

ISSN: 1473-3099